A Study of GD007 (Human iPSC-Exosome Liquid Dressing) for Safety and Dose-Finding in Moderate-Severe Intrauterine Adhesions

Summary

Intrauterine adhesions (IUA) remain highly prevalent in China, with incidence rates steadily increasing due to the rising number of intrauterine procedures. Literature reports indicate that IUA caused by repeated induced abortions, curettage, postpartum infections, and other intrauterine surgeries occurs in 25%-30% of cases, making it a leading cause of reduced menstrual flow, cyclic abdominal pain, recurrent miscarriage, and secondary infertility, significantly impairing women's reproductive health and overall well-being.

Currently, no effective treatment exists for severe IUA to fully restore fertility and normal menstrual physiology. The commonly used hysteroscopic adhesiolysis (TCRA) has a high recurrence rate of 62.5%, with a post-operative pregnancy success rate of only 22.5%-33.3%. Therefore, there is an urgent clinical need to explore novel therapeutic strategies for severe intrauterine adhesions.

Exosomes derived from induced pluripotent stem cells (iPS-Exo) offer significant advantages over MSC-derived exosomes due to their clonal origin, ensuring superior batch-to-batch consistency and stability. This feature enables more stringent quality control standards and facilitates standardized, scalable production and quality management systems. Compared to mesenchymal stem cells (MSCs) or MSC-derived exosomes, iPS-Exo exhibit multiple superior properties:

1. Higher potency of bioactive components:

* As iPSCs represent an earlier differentiation stage than MSCs, iPS-Exo contain elevated levels of functional factors such as TGF-β (anti-inflammatory), BDNF (neurotrophic), and others.
* Demonstrated biological effects:

* Anti-apoptosis
* Inflammation suppression
* Angiogenesis promotion
* Fibrosis inhibition
* Enhanced tissue repair potential
2. Enhanced pharmaceutical suitability:

* Clonal expansion ensures product homogeneity and manufacturing reproducibility.
* Simplified quality control metrics compared to heterogeneous MSC-Exo.
3. Genetic engineering compatibility:

o Amenable to precision modification for targeted therapeutic enhancement.
4. Preclinical efficacy evidence:

* Neuroprotection: Superior to MSC-Exo in mitigating neuronal damage induced by oxygen-glucose deprivation and hydrogen peroxide-induced oxidative stress.
* Epilepsy models: Significant reduction in seizure frequency/severity and decreased cerebral IL-6/TNF-α levels in treated mice.
* Stroke models: Intravenous administration:

* Suppressed Th1/Th17 immune responses post-ischemia
* Increased Treg cell proportion
* Modulated immune microenvironment
* Reduced infarct volume and improved motor function
* Enhanced survival rates Compared to small-molecule drugs or MSC-Exo with limited mechanisms, iPS-Exo demonstrate broader therapeutic potential for ischemic stroke, drug-resistant epilepsy, and other disorders. However, their application in treating endometrial damage from intrauterine adhesions (IUA) remains unexplored to date.

Goodain (Beijing) Pharmaceutical Technology Co., Ltd., a biotechnology company specializing in induced pluripotent stem cells (iPSCs) and exosome technologies, holds GMP laboratory certification. The company has independently developed clinical-grade iPSC-derived exosomes (iPS-Exo), which have been investigated in four investigator-initiated exploratory clinical trials across different indications, with no reported adverse events (AEs) or serious adverse events (SAEs) to date.

Preclinical Rationale

Our research team previously conducted preclinical studies using umbilical cord mesenchymal stem cell-derived exosomes (MSC-Exo) in a rat model of intrauterine adhesions (IUA). Results demonstrated that:

• Intrauterine perfusion of MSC-Exo significantly promoted:

* Endometrial regeneration in mechanically injured rats
* Increased endometrial gland density
* Enhanced cellular proliferation
* Higher embryo implantation rates These findings support the translational potential of exosome-based therapies for IUA.

Study Objective

Building on this preclinical evidence, we propose the first-in-human safety evaluation of clinical-grade iPS-Exo for moderate-to-severe IUA. This study aims to:

1. Establish preliminary safety profiles
2. Explore therapeutic efficacy signals
3. Address the unmet clinical need in severe IUA management Key Advantages

* Regulatory-ready: GMP-certified production ensures batch consistency.
* Clinical precedence: Favorable safety data from prior exploratory trials.
* Mechanistic validation: Proven endometrial repair effects in animal models.

Conditions

• Moderate-Severe Intrauterine Adhesions

Interventions

DRUG

GD007 Low-dose drug group

o Eligible patients who provide informed consent will receive: * First exosome perfusion: 24 hours post-operatively * Subsequent perfusions: Every 3 days (total 3 perfusions)

DRUG

GD007 Mid-dose drug group

* Patients diagnosed with moderate-to-severe intrauterine adhesions (IUA) will undergo standard hysteroscopic adhesiolysis. * Eligible patients who provide informed consent will receive: * First exosome perfusion: 24 hours post-operatively * Subsequent perfusions: Every 3 days (total 3 perfusions)

DRUG

GD007 High-dose drug group

* Patients diagnosed with moderate-to-severe intrauterine adhesions (IUA) will undergo standard hysteroscopic adhesiolysis. * Eligible patients who provide informed consent will receive: * First exosome perfusion: 24 hours post-operatively * Subsequent perfusions: Every 3 days (total 3 perfusions)

DRUG

GD007 Blank Control drug Group

* Patients diagnosed with moderate-to-severe intrauterine adhesions (IUA) will undergo standard hysteroscopic adhesiolysis. * Eligible patients who provide informed consent will receive: * First exosome perfusion: 24 hours post-operatively * Subsequent perfusions: Every 3 days (total 3 perfusions)

Sponsors & Collaborators

• The First Affiliated Hospital with Nanjing Medical University

  lead OTHER

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

SEQUENTIAL

Eligibility

Min Age

20 Years

Max Age

40 Years

Sex

FEMALE

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-05-04

Primary Completion

2026-05-30

Completion

2026-12-31

Countries

• China

Study Locations